Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β

J Clin Immunol. 2021 Oct;41(7):1425-1442. doi: 10.1007/s10875-021-01068-6. Epub 2021 Jun 8.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Animals
  • Autoantibodies / metabolism
  • B-Lymphocytes / immunology*
  • COVID-19 / immunology*
  • COVID-19 / therapy
  • COVID-19 Serotherapy
  • Humans
  • Immunization, Passive
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunotherapy / methods*
  • Interferon Type I / immunology
  • Interferon Type I / metabolism
  • Interferon-beta / therapeutic use*
  • Lymphocyte Depletion
  • Plasmapheresis / methods*
  • Protein Kinase Inhibitors / therapeutic use*
  • SARS-CoV-2 / physiology*
  • Vaccination

Substances

  • Autoantibodies
  • Immunoglobulins, Intravenous
  • Interferon Type I
  • Protein Kinase Inhibitors
  • Interferon-beta